To compare single-step transepithelial photorefractive keratectomy (TPRK) to conventional alcohol assisted epithelial removal then photorefractive keratectomy (AAPRK) regarding pain, epithelial healing, visual acuity, corneal haze measured subjectively and objectively, higher order aberrations changes, contrast sensitivity and vector analysis of astigmatic correction with one year follow-up. A prospective double-blind randomized study of 29 subjects (58 eyes) who underwent myopic aberration-free laser correction by smart pulse technology using Schwind Amaris 1050 Hz with 1-year follow-up. Right eye was randomly treated by AAPRK or TPRK. Postoperative assessment was performed on day 1 and 3, at 1st week, and 1st, 3rd, 6th, and 12th months. Patients were assessed for pain, epithelial healing, visual acuity, corneal haze, astigmatic correction, higher order aberrations and contrast sensitivity. Epithelial healing was complete by the 3rd day in 62.1% of AAPRK eyes and in 89.7% of TPRK eyes. First day postoperative pain was higher in TPRK group (p = 0.0134). The decimal uncorrected visual acuity at 12 months was 1.47 ± 0.39 and 1.57 ± 0.38 in the AAPRK and TPRK groups respectively (p = 0.3719). Post-photorefractive keratectomy haze reached a final level of 0.04 ± 0.14 and 0.02 ± 0.1 in AAPRK and TPRK groups respectively (p = 0.5607). Contrast sensitivity was comparable in low and high frequency cycles per degree. Vector analysis of astigmatic correction showed correction index at one year of 0.99 and 1.05 for AAPRK and TPRK groups respectively. Alcohol assisted and transepithelial photorefractive keratectomy have comparable results regarding safety and efficacy.
Purpose: To compare the measured or calculated angle Kappa using Oculus pentacam HR, Sirius and Orbscan III devices. Patients and methods: A prospective randomized cohort study, conducted on 47 eyes of 47 healthy orthotropic individuals, with an age range of 18–50 years and a corrected Snellen’s distance visual acuity (CDVA) of 0.8 decimal or better. Angle Kappa is assessed directly using Orbscan® III software version 1.8.165.1. (Bausch and Lomb Rochester, New York, United States), while Pentacam® HR 1.21r.65 (Oculus Optikgeräte GmbH, Wetzlar, Germany) and Sirius device (CSO, version 3.2.1.60, Costruzione Strumenti Oftalmici, Florence, Italy) were used to calculate angle kappa indirectly. Results: Least mean difference of estimated angle Kappa was between Orbscan and Pentacam devices (− 0.18° ± 1.8), and it was statistically insignificant (p value = 0.1294). Differences between both Orbscan and Sirius, and Pentacam and Sirius were statistically significant (p value = 0.0004 and < 0.0001 consecutively). Bland Altman analysis showed a 95% confidence interval between Orbscan III and Pentacam of − 3.76 to 3.4 and between Orbscan III and Sirius of − 3.79 to 2.26. Conclusion: Pentacam parameters can be used as a reliable method to calculate angle kappa indirectly, without usage of any additional measurements from other machine. Sirius device parameters could also be used, but with less accurate results. A simple modification to those devices’ software to calculate it, and incorporate it in the printout is possible, and highly recommended.
4 March 2023 in Graefe's Archive for Clinical and Experimental Ophthalmology
Purpose: To evaluate the indications, outcomes, and complications of the usage of Aurolab Aqueous Drainage Implant (AADI) using mitomycin-C. Methods: A retrospective case series of patients who underwent AADI placement using mitomycin-C between April 2018 and June 2020 at Ain Shams University Hospitals, Cairo, Egypt. The data was extracted from the records of the patients with a minimum of 1 year of follow-up. Complete success was defined as IOP ≥ 5 mmHg and ≤ 21 mmHg or reduction of IOP by ≥ 20% from baseline without antiglaucoma medications (AGMs). Qualified success was defined as reaching the same IOP range with the aid of AGM. Results: A total of 50 eyes of 48 patients were included. Neovascular glaucoma represented the commonest indication (13 patients, 26%). The mean preoperative IOP was 34.0 ± 7.1 mmHg, with a median number of AGM of 3 (mean ± SD = 2.84 ± 1), while the mean IOP after 12 months was 14.3 ± 4 with a median number of AGM of 0. (mean ± SD = 0.52 ± 0.89) (p < 0.001). Complete success was achieved in 33 patients (66%). Qualified success was achieved in 14 patients (28%). Thirteen eyes (26%) had variable postoperative complications; none of them required explantation of the device or affected the visual acuity (except one patient). Conclusion: AADI with using mitomycin-C and ripcord during the surgery is an effective and relatively safe method of control of IOP in refractory and advanced cases of glaucoma, with an overall success rate of 94%.
Purpose: To evaluate the effect of intrastromal injection of anti-vascular endothelial growth factor (Anti-VEGF) on corneal neovascularization using spectral domain Optical coherence tomography angiography imaging (OCTA). Patients and methods: This is a pilot study that was conducted on 10 eyes of 10 patients with corneal neovascularization who were planned for keratoplasty or after keratoplasty. Intrastromal injection of 5 mg/0.2 ml [2.5%] bevacizumab using a 30 Gauge needle was performed. OCTA was done 48 h before the injection, 1 week and 1 month after the injection. OCTA images were compared to evaluate the effect of Anti-VEGF on corneal neovascularization. Results: Comparing the OCTA pictures with the preoperative period, at 1 week period, 9 cases have shown decreased corneal neovascularization, with only 1 case that has not changed and seemed to be unresponsive to the single injection of Anti-VEGF. At 1 month period, 8 cases re-vascularized again but none of them reached the preoperative level, 1 case had decreased vascularization (completely disappeared) and 1 case remained the same with no change. Conclusion: A single injection of bevacizumab has a temporal effect on corneal neovascularization. No local or systemic complications have been noted. OCTA was able to visualize vessels in 3-D image, even under vascularized corneal scars. OCTA was able to recognize subtle changes in corneal neovascularization that were not visible by slit lamp.
21 October 2026 in Journal of the Egyptian Ophthalmological Society
Purpose: To assess the efficacy and safety of a novel technique of combining silicone oil removal (SOR) and endo-cyclophotocoagulation using the endolaser of the vitrectomy machine in patients with silicone induced glaucoma. Design: Prospective interventional pilot study. Patients and methods: Ten eyes with silicone induced glaucoma underwent combined SOR and endo-cyclophotocoagulation using the endolaser probe of the vitrectomy machine. The extent of application was determined by the morphology of the ciliary processes (180, 270, or 360°) and a power of 400 mW, increased or decreased in increments of 50 mW, until slight blanching of the ciliary process was used. Detailed data of the vitrectomy surgery (indication, silicone oil type, duration,…etc.) were retrieved. Pre- and postoperative intraocular pressure, best corrected visual acuity, and number of antiglaucoma medications were recorded at 1 week, 1 month, 3 months and 6 months postoperative. Intra- or postoperative complications were recorded. Results: Seven cases had 180°, two had 270°, and one patient had 360° laser application. Intraocular pressure and number of antiglaucoma medications reduction was achieved in 9 patients, with a statistically significant difference at the 6-month follow-up ( P =0.00 for both). Best corrected visual acuity showed improvement postoperatively but the change was insignificant ( P =0.21). The only postoperative complication encountered was the inflammatory reaction that was noted in nine patients, and subsided with topical treatment within an average of 9.1 (±4.725) days without any sequelae. Conclusion: Combined SOR with endolaser cyclophotocoagulation using the conventional vitrectomy machine laser probe is a promising approach silicone induced glaucoma patients, with high efficacy and minimal complications.